Starling Oncology, Inc.
Income Statement
| Line Item | Jul 2026 | Jun 2026 | Apr 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $161.3M | — | $147.4M | — | — | — | $136.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $29.9M | — | $28.2M | — | — | — | $25.3M |
| Operating Income | — | $-4.6M | — | $-6.5M | — | — | — | $-8.1M |
| Operating Margin | — | -2.9% | — | -4.4% | — | — | — | -5.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-9.8M | — | $-2.5M | — | — | — | $-16.5M |
| Income Tax Expense | — | $0 | — | $0 | — | — | — | $0 |
| Net Income | — | $-9.8M | — | $-2.5M | — | — | — | $-16.5M |
| Net Margin | — | -6.1% | — | -1.7% | — | — | — | -12.1% |
| EPS (Basic) | — | $-0.08 | — | $-0.02 | — | — | — | $-0.14 |
| EPS (Diluted) | — | $-0.08 | — | $-0.02 | — | — | — | $-0.14 |
| Shares Outstanding (Basic) | 101.9M | 103.0M | 100.0M | 101.8M | 98.8M | 98.9M | 98.4M | 97.5M |
| Shares Outstanding (Diluted) | 101.9M | 103.0M | 100.0M | 101.8M | 98.8M | 98.9M | 98.4M | 97.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |